Chronic Myelogenous Leukemia (CML)

In this article, we have covered the following aspects of Chronic Myelogenous leukemia (CML):

  • Best Hospitals for treatment of CML
  • Top Hemato Oncologists for treatment of CML
  • Cost of CML treatment in India
  • Understanding Chronic Myelogenous Leukemia

Best Doctors and Hospitals for treatment of CML

Following is a list of the most reputed specialists in India for the treatment of Chronic Myelogenous Leukemia.
Please click the ‘contact doctor‘ button on the right side for seeking opinion or requesting an appointment with your chosen specialist.
(*On mobile device, please click the ‘+’ symbol on the left to access the contact form)

Doctor ImageDr. NameSpecialtyHospital AssociatedContact DoctorCity
Dr. Rahul BhargavaDr. Rahul BhargavaHaemato OncologistFortis Memorial Research InstituteGurgaon
Dr. Vikas DuaDr. Vikas DuaHaemato OncologistFortis Memorial Research InstituteGurgaon
Dr. Prantar ChakrabartiDr. Prantar ChakrabartiHaemato OncologistFortis Hospital AnandapurKolkata
Dr. satya prakash yadavDr. Satya Prakash YadavHaemato OncologistMedanta - The MedicityGurgaon
Dr Hari GoyalDr. Hari GoyalHaemato OncologistArtemis HospitalGurgaon
Dr Santanu SenDr. Santanu Sen Haemato OncologistKokilaben Dhirubai Ambani HospitalMumbai
Dr. Shishir SethDr. Shishir SethHaemato OncologistIndraprastha Apollo HospitalNew Delhi
Dr Dharma ChoudharyDr. Dharma ChoudharyHaemato OncologistBLK Super Specialty HospitalDelhi
Dr. Sharat DamodarDr. Sharat DamodarBone Marrow TransplantNarayana Multispeciality HospitalBangalore

Cost of treatment for CML in India

Unfortunately, we are not able to share the cost of this treatment as we are still awaiting response from few hospitals before publishing the cost. However, you may share your medical reports and we will share the cost of treatment from the hospital recommended for you.

Understanding Chronic Myelogenous leukemia

In Chronic Myelogenous Leukemia (CML), the bone marrow makes immature granulocytes (a type of white blood cells), which interfere with the normal production of blood cells. The immature WBCs from the bone marrow enter into the bloodstream throughout the body, which leads to anemia and bleeding. Mostly CML occurs in male adults compared to females and rarely develops in children. Also known as Chronic Myeloid Leukemia, it accounts for 20% of all leukemia patients.

CML is caused by a single, specific genetic mutation and progresses through three phases – chronic, accelerated, and blast. In most cases, the disease is diagnosed in the chronic phase, which then progresses to the accelerated and blast phases after three to five years.

Signs and symptoms of CML

  • Fatigue, weight loss, loss of energy, decreased exercise tolerance
  • Fever, excessive sweating
  • Anemia, unexplained bleeding
  • Frequent or repeated infections and slow healing
  • Increase in WBC count or enlargement of spleen on routine assessment
  • Fullness and decreased food intake
  • Left upper abdominal pain from spleen infarction
  • Hepatomegaly (enlarged liver)
  • Symptoms of progressive phase CML (accelerated and blast phase):
    • Bleeding, petechiae, and ecchymoses during the acute phase
    • Bone pain and fever in the blast phase
    • Increasing anemia, thrombocytopenia, basophilia, and a rapidly enlarging spleen

Investigations required in CML

  • CBC with differential
  • Peripheral blood smear
  • Bone marrow analysis

The definitive diagnosis of CML is based on the following:

  • Histopathologic findings in the peripheral blood
  • Philadelphia (Ph) chromosome in bone marrow cells

Treatment of CML

The treatment of CML varies with the phase of disease, age, and general health of the patient. The goal of the treatment during the chronic phase is to control CML and keep the blood counts within a normal range. The treatment in the accelerated and blast phase is more intensive.

The treatment of CML involves:

  • Chemotherapy
  • Bone Marrow Transplant

Bone marrow transplant is the only hope chance for a definitive cure for Chronic Myeloid leukemia. Ideally, allogenic BMT is performed in the chronic phase of the disease with a matched or single-antigen-mismatched related donor. Overall survival of allogenic BMT via matched unrelated donors is 31% to 43% for patients younger than 30 years, and from 14% to 27% for older patients.

Note (for foreign patients):

Besides South Asian countries (Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan, Sri Lanka), every year, India gets thousands of medical tourists from African countries- Nigeria, Kenya, Ethiopia, Sudan, Uganda, Ghana, Somalia,Gambia etc and Middle Eastern countries like Iraq, Iran, Saudi Arabia, Oman, UAE, Yemen etc. Hence, if you are a citizen of any of these countries, there is good likelihood that you will be meeting some fellow citizens or same language speakers in the major hospitals in India. Almost all the top hospitals have translators for people of these region. Our patient support team is also well placed to assist you.

Need Assistance?

Medical Tourism-Flow Chart

© Copyright 2018 MedGurus. All rights reserved.

Contact Us
Contact us
Name of person enquiring
Please skip this if you are the patient
Country Code + Contact number
Please enter a valid email address that you check regularly
Mention medical condition in detail & assistance needed. You can send your medical reports to:
error: Content is protected !!